Validation of Continuous Noninvasive Haemoglobin Monitoring by the Radical 7 Pulse CO-Oximetry Monitor After in Vivo Adjustment.

August 16, 2015 updated by: Juan Soliveres, Hospital Universitario Doctor Peset

Validation of a Continuous Noninvasive Haemoglobin Determination Monitor (Radical 7 Pulse CO-Oximeter, SpHb) Compared to the Central Laboratory Coulter (LabHb) and a Point of Care (POC) Invasive Cooximeter (COoxHb) After in Vivo Adjustment.

Continuous haemoglobin determination could improve the outcomes of several patients in risk of bleeding during surgery. An in vivo calibration has been introduced to the device after our team found its need. The uncalilbrated validation of the Masimo Radical 7 continuous haemoglobin monitor has been made in various papers, although it has been compared to point of care devices, thus introducing an error as such point of care devices although validated for haemoglobin determination, are not as accurate as the gold standard. The validation of the gold standard calibrated device has not been described yet.

When compared to the accepted gold standard (cyanmethemoglobin method, Coulter), accuracy and precision of the continuous haemoglobin monitor could be good enough to be used interchangeably with the gold standard.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Continuous haemoglobin determination could improve the outcomes of several patients in risk of bleeding during surgery.

The in vivo calibration has not been adjusted to the gold standard haemoglobin determination in the literature yet.

Two blood samples will be withdrawn at the same time from an arterial line, one for the central laboratory and the other one for the POC device. At the same exact time the SpHb measurement will be recorded. At least eight samples are expected per patient. A maximum of 20 samples will be withdrawn per patient.

To compare bias, precision and limits of agreement among SpHb, LabHb and COoxHb the Bland Altman method will be used with multiple observations per subject when the true value varies. An error grid analysis will be made to know how it could affect to clinical decision making.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valencia, Spain, 46023
        • Recruiting
        • University Hospital Doctor Peset
        • Contact:
          • Juan Soliveres, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients scheduled to any surgery of at least three hours of duration.

Description

Inclusion Criteria:

  • Adult patients.
  • Surgery duration of at least two hours.
  • Patients scheduled to surgery under general anaesthesia and muscle relaxation.
  • Radial arterial line needed for blood pressure control or other reason not related to the study.

Exclusion Criteria:

  • Radial arterial line not indicated / not possible to place.
  • Sampling difficult or impossible.
  • Need to reposition arterial line arm during surgery.
  • Any illness that could influence the haemoglobin measurement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Central coulter bias and limits of agreement
Time Frame: 3 months
Bias and limits of agreement of SpHb compared to the central laboratory coulter
3 months
Central coulter bias and limits of agreement after in vivo calibration
Time Frame: 3 months
Bias and limits of agreement of SpHb compared to the central laboratory coulter after in vivo Radical 7 calibration
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
POC Cooximeter bias and limits of agreement
Time Frame: 3 months
Bias and limits of agreement of SpHb compared to the POC cooximeter
3 months
POC Cooximeter bias and limits of agreement
Time Frame: 3 months
Bias and limits of agreement compared to the POC cooximeter after in vivo Radical 7 calibration
3 months
POC Cooximeter Coulter interchangeability
Time Frame: 3 months
Bias and limits of agreement of POC Cooximeter Hb determination compared to the central laboratory coulter
3 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of bias and limits of agreement
Time Frame: 3 months
Comparison of bias and limits of agreement among central laboratory, POC cooximeter and SpHb continuous monitor.
3 months
Clinical decision making
Time Frame: 3 months
Error grid analysis plot
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Juan Soliveres, MD, PhD, University Hospital Doctor Peset

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Soliveres J, Balaguer J, Estruch M, Sánchez A, Sánchez J. Validation of Continuous and Noninvasive Hemoglobin Monitoring from Pulse CO-Oximetry during Surgery. 2010 Annual Meeting of the American Society Anesthesiologists

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

June 1, 2015

Study Completion (Anticipated)

September 1, 2015

Study Registration Dates

First Submitted

March 22, 2015

First Submitted That Met QC Criteria

March 25, 2015

First Posted (Estimate)

March 26, 2015

Study Record Updates

Last Update Posted (Estimate)

August 18, 2015

Last Update Submitted That Met QC Criteria

August 16, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • CEIC:47/10

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sphb Haemoglobin in Vivo Validation

Clinical Trials on Masimo Radical 7

3
Subscribe